Zweig-DiMenna Associates’s AbbVie ABBV Stock Holding History

Zweig-DiMenna Associates’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	–	Sell	-337,000	Closed	-$19.5M	–	261
2014 Q3	$19.5M	Buy	+337,000	New	+$18.7M	0.85%	44

Other funds holding ABBV

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Zweig-DiMenna Associates's ABBV Position: Q2 2018 in Review

Zweig-DiMenna Associates sold out of AbbVie (ABBV) in Q2 2018, closing a stake of 2,300 shares — an estimated $218K sold.

Zweig-DiMenna Associates first reported a position in ABBV in Q2 2013 and held it in 8 quarters. The position peaked at $24.2M in Q2 2013. 1,997 funds tracked by Wall St. Rank hold ABBV as of Q2 2018.

Zweig-DiMenna Associates reported no remaining AbbVie position as of Q2 2018 after selling out during the quarter.
Zweig-DiMenna Associates sold 2,300 AbbVie shares in Q2 2018, an estimated $218K.
Zweig-DiMenna Associates first reported a position in AbbVie in Q2 2013 and held it in 8 quarters.
Zweig-DiMenna Associates's AbbVie position peaked at $24.2M in Q2 2013.
1,997 funds tracked by Wall St. Rank held AbbVie as of Q2 2018.

Based on Zweig-DiMenna Associates's 13F filing for Q2 2018, filed 1 Aug 2018.